Gilead, GSK eye bigger PAH market with Phase III combo data
This article was originally published in Scrip
Executive Summary
Gilead Sciences and GlaxoSmithKline reported on 8 September that their drug Letairis (ambrisentan) combined with Eli Lilly's Adcirca (tadalafil) reduced the risk of clinical failure in patients with pulmonary arterial hypertension (PAH) by 50% compared with ambrisentan and tadalafil on their own (p=0.0002), but not without increased safety concerns for PAH patients.